Welcome to our dedicated page for VERTEX PHARMACEUTICALS / MA SEC filings (Ticker: VRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on VERTEX PHARMACEUTICALS / MA's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into VERTEX PHARMACEUTICALS / MA's regulatory disclosures and financial reporting.
Vertex Pharmaceuticals reported a compensation-related equity grant to EVP and Chief Regulatory & Quality Officer Ourania Tatsis. She acquired 8,251 shares of common stock in the form of a restricted stock unit award on 07/21/2026, vesting on 03/31/2030, bringing her direct holdings to 53,572 shares.
Vertex Pharmaceuticals executive Amit Sachdev reported an acquisition of 8,251 shares of common stock on 2026-07-21 through a restricted stock unit award that vests on 03/31/2030. Following this award, he holds 66,512 shares directly, plus 882 shares indirectly via a 401(k) and 6,637 shares held in trust.
SACHS BRUCE I reported acquisition or exercise transactions in this Form 4 filing.
Vertex Pharmaceuticals director Bruce I. Sachs received a grant of 99.941 deferred stock units on July 15, 2026 at $475.28 per unit. Each unit represents one share of common stock, payable upon his board service ending, a change of control, disability, or death, bringing his directly held deferred stock units to 15,771.807.
Garber Alan M reported acquisition or exercise transactions in this Form 4 filing.
Vertex Pharmaceuticals director Alan M. Garber received a grant of 31.56 deferred stock units on July 15, 2026. Each unit represents one share of common stock and will be paid in shares upon the earliest of his board service termination, a change of control, or his disability or death. Following this award, he directly holds 65.458 deferred stock units tied to Vertex common stock.
Vertex Pharmaceuticals executive Ourania Tatsis reported an open-market sale of 1,500 shares of Common Stock. The transaction took place on July 2, 2026 at a price of $524.99 per share. The filing states that the sale was made pursuant to a company-approved Rule 10b5-1 trading plan entered into on August 21, 2025, indicating it was pre-scheduled. After this transaction, Dr. Tatsis directly holds 45,321 shares of Vertex Pharmaceuticals common stock.
Vertex Pharmaceuticals executive Duncan McKechnie, EVP and Chief Commercial Officer, sold 1,541 shares of Common Stock in an open-market transaction at $519.00 per share on July 2, 2026. Following this sale, he directly holds 11,001 shares. The transaction was made under a company-approved trading plan pursuant to Rule 10b5-1 entered into on November 25, 2025, indicating it was pre-scheduled rather than discretionary.
Vertex Pharmaceuticals plans to acquire Crinetics Pharmaceuticals in an all-cash deal at $85.00 per share, implying a $10.0 billion equity value, or $8.8 billion net of cash. Crinetics will become a wholly owned subsidiary following the merger, which is expected to close in the third quarter of 2026, subject to shareholder and regulatory approvals.
Vertex expects to finance the transaction with cash on hand and a $4.5 billion unsecured 364‑day bridge loan facility. Management highlights the commercialized acromegaly drug PALSONIFY and late‑stage atumelnant for congenital adrenal hyperplasia as key strategic assets, targeting more than $5 billion in potential annual revenue and accretion to non‑GAAP operating income in 2029.
Vertex Pharmaceuticals executive Joy Liu reported an open-market sale of company stock. On July 1, 2026, she sold 828 shares of Vertex common stock at an average price of $502.71 per share.
After this transaction, Liu directly holds 19,131 Vertex shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan that she entered into on November 25, 2025, indicating the trades were scheduled in advance rather than timed at her discretion.
Vertex Pharmaceuticals reported a proposed sale notice on Form 144 listing 1,541 shares of Common Stock associated with Fidelity Brokerage Services LLC. The filing also lists restricted stock vesting events of 612 shares on 02/17/2026 and 929 shares on 02/24/2026.